symport

(redirected from Cotransporter)
Also found in: Wikipedia.

symport

 [sim´port]
a transport mechanism that moves two compounds simultaneously across a cell membrane in the same direction, one compound being transported down a concentration gradient and the other against a gradient. See also antiport and cotransport.

sym·port

(sim'pōrt),
Coupled transport of two different molecules or ions through a membrane in the same direction by a common carrier mechanism (symporter). Compare: antiport, uniport.
[sym- + L. porto, to carry]

symport

/sym·port/ (sim´port) a mechanism of transporting two compounds simultaneously across a cell membrane in the same direction, one compound being transported down a concentration gradient, the other against a gradient.

sym·port

(sim'pōrt)
Coupled transport of two different molecules or ions through a membrane in the same direction by a common carrier mechanism (symporter).
Compare: antiport, uniport
[sym- + L. porto, to carry]

symport

a structure that transports two compounds simultaneously across a cell membrane in the same direction, one compound being transported down a concentration gradient, the other against a gradient.
References in periodicals archive ?
The CANVAS Program is the longest, largest and broadest known completed CV outcomes program of any sodium glucose cotransporter 2 (SGLT2) inhibitor to date and was the first to assess the efficacy, safety, and durability of canagliflozin in more than 10,000 patients with T2D who had either a prior history of CV disease or at least two CV risk factors.
Food and Drug Administration (FDA) has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.
In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylurea, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used.
Delphinol[R] standardized maqui berry extract reduces postprandial blood glucose increase in individuals with impaired glucose regulation by novel mechanism of sodium glucose cotransporter inhibition.
We round things off with our continuing education series on the role that sodium glucose cotransporter 2 inhibitors, a new class of antihyperglycemic agents in the treatment of type 2 diabetes, plays in the kidneys.
3,4 Glucagon like peptide-1 receptor agonists (GLP1RA), dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are modern classes of glucose lowering drugs with lower risk of hypoglycaemia.
In conjuction, QTERN combines two anti-hyperglycemic agents with complementary mechanisms of action in a once-daily tablet: Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor; and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, added the company.
Empagliflozin belongs to a class of drugs known as sodium glucose cotransporter 2 (SGLT2) inhibitors.
Regulation of small intestinal Na-Pi type lib cotransporter by dietary phosphate intake.
Our previous study showed that neonatal exposure to sevoflurane induced acute seizure-like activity and was blocked by bumetanide (a Na [sup]+-K [sup]+-2Cl [sup]− cotransporter 1 [NKCC1] inhibitor) through reversing sevoflurane-induced apoptosis.
2005)]; sodium potassium chloride cotransporter 2 [Slc12a2, F: GAACCTTTT GAGGATGGC, R: CACGATCCATGACAA TCT (Castrop et al.